Skip to search formSkip to main contentSkip to account menu

MLN2238

Known as: MLN-2238 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Boron CompoundsGlycineixazomib
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells
Abstract Inhibition of the proteasome has emerged as a clinically effective anticancer therapeutic approach in recent years… 
2016
2016
BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition.
2016
2016
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma
The ubiquitin-proteasome signaling pathway is critical for cell cycle regulation and neoplastic growth. Proteasome inhibition can… 
Highly Cited
2014
Highly Cited
2014
Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease
Purpose: MLN9708 (ixazomib citrate), which hydrolyzes to pharmacologically active MLN2238 (ixazomib), is a next-generation… 
Highly Cited
2014
Highly Cited
2014
Proteasome Inhibitors Alter Levels of Intracellular Peptides in HEK293T and SH-SY5Y Cells
The proteasome cleaves intracellular proteins into peptides. Earlier studies found that treatment of human embryonic kidney 293T… 
Review
2013
Review
2013
Proteasome inhibitors in acute leukemia
Proteasome inhibition has been recognized as a novel treatment modality in hematologic malignancies. Initially, the reversible… 
2013
2013
18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome…
18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are useful imaging modalities for… 
Highly Cited
2012
Highly Cited
2012
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.
miRs play a critical role in tumor pathogenesis as either oncogenes or tumor-suppressor genes. However, the role of miRs and… 
Review
2011
Review
2011
Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases
Recent advances in the development and discovery of pharmacological interventions within the ubiquitin–proteasome system (UPS… 
Highly Cited
2011
Highly Cited
2011
Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)